Holen Sie sich die Stockscreener-App
8.21
2.15%
-0.18
Schlusskurs vom Vortag:
$8.39
Offen:
$8.45
24-Stunden-Volumen:
705.45K
Relative Volume:
0.48
Marktkapitalisierung:
$729.08M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-3.6489
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
+1.92%
1M Leistung:
-6.49%
6M Leistung:
+69.98%
1J Leistung:
+64.53%
1-Tages-Spanne:
$8.12
$8.76
1-Wochen-Bereich:
$7.67
$9.0364
52-Wochen-Spanne:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.21 | 745.07M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Mood: Is Personalis Inc showing insider buyingTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Personalis, Inc. (PSNL) Stock Analysis: Evaluating a 34.51% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Aug Patterns: Will Personalis Inc outperform small cap indexesJuly 2025 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Why Personalis Inc. stock could benefit from AI revolutionWeekly Earnings Recap & Consistent Growth Equity Picks - mfd.ru
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Personalis Data Breach Potentially Exposes PII and PHI - Claim Depot
Medicare Now Covers NeXT Personal® MRD Testing for Lung Cancer SurveillancePersonalis, Inc. - Oncodaily
Personalis (NASDAQ:PSNL) Price Target Raised to $13.00 - MarketBeat
Medicare approves Personalis’ lung cancer test for surveillance By Investing.com - Investing.com Canada
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Investment Magazine
Personalis (PSNL) Gains 10% Following Medicare Coverage for Canc - GuruFocus
Personalis (NASDAQ:PSNL) Shares Gap UpShould You Buy? - MarketBeat
Personalis wins Medicare coverage for NeXT Personal (PSNL) - Seeking Alpha
Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com - Investing.com India
Personalis stock rises after Medicare approves lung cancer test coverage - Investing.com
Why Is Personalis Stock Soaring Tuesday?Personalis (NASDAQ:PSNL) - Benzinga
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Asianet Newsable
Personalis rises as Medicare extends coverage to lung cancer test - TradingView
Personalis Inc receives Medicare coverage for Next Personal in lung cancer surveillance - marketscreener.com
Medicare approves Personalis’ lung cancer test for surveillance - Investing.com
Personalis Inc Receives Medicare Coverage For Next Personal In Lung Cancer Surveillance - TradingView
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
Revenue Check: Can Personalis Inc stock double in the next yearJuly 2025 Reactions & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL - MarketBeat
Breakthrough Cancer Monitoring Technique Fuels Growth for Personalis - AD HOC NEWS
Aug Final Week: Is Personalis Inc showing insider buyingLong Setup & AI Enhanced Trading Signals - baoquankhu1.vn
Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance
Personalis (PSNL) Study Highlights NeXT Personal's Impact in Can - GuruFocus
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - MarketBeat
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Guggenheim Raises Price Target for Personalis (PSNL) to $13.00 | PSNL Stock News - GuruFocus
Gainers Report: Is Personalis Incs growth already priced inShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy? - Defense World
Hedge Fund Bets: Should you avoid Personalis Inc stock right nowEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Personalis, Inc. $PSNL Shares Purchased by AIGH Capital Management LLC - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares - Investing.com Nigeria
Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares By Investing.com - Investing.com Australia
Personalis (NASDAQ:PSNL) Reaches New 12-Month HighWhat's Next? - MarketBeat
Personalis Sees Revised Reimbursement Rates for Cancer Tests - MSN
Personalis (NASDAQ:PSNL) Trading 14.8% HigherStill a Buy? - MarketBeat
Aug Swings: Can Personalis Inc stock double in the next yearJuly 2025 Sector Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Market Rankings: How does PLRX perform in inflationary periodsWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
How A New Price Target Is Shaping The Evolving Story For Personalis (PSNL) - Yahoo Finance
Winners Losers: Is Personalis Incs growth already priced inDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Personalis Inc-Aktie (PSNL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tempus AI, Inc. | 10% Owner |
Nov 25 '25 |
Buy |
10.62 |
23,600 |
250,665 |
12,918,346 |
| Tempus AI, Inc. | 10% Owner |
Dec 22 '25 |
Buy |
8.93 |
28,000 |
250,040 |
13,039,067 |
| Tempus AI, Inc. | 10% Owner |
Nov 21 '25 |
Buy |
9.40 |
26,499 |
249,190 |
12,869,521 |
| Tempus AI, Inc. | 10% Owner |
Nov 24 '25 |
Buy |
9.87 |
25,225 |
248,971 |
12,894,746 |
| Tempus AI, Inc. | 10% Owner |
Nov 19 '25 |
Buy |
8.12 |
30,645 |
248,837 |
12,814,195 |
| Tempus AI, Inc. | 10% Owner |
Nov 20 '25 |
Buy |
8.63 |
28,827 |
248,777 |
12,843,022 |
| Tempus AI, Inc. | 10% Owner |
Dec 17 '25 |
Buy |
7.86 |
31,650 |
248,769 |
12,949,996 |
| Tempus AI, Inc. | 10% Owner |
Dec 19 '25 |
Buy |
8.39 |
29,641 |
248,688 |
13,011,067 |
| Tempus AI, Inc. | 10% Owner |
Dec 18 '25 |
Buy |
7.91 |
31,430 |
248,611 |
12,981,426 |
| Tachibana Aaron | CFO AND COO |
Jan 22 '26 |
Option Exercise |
9.16 |
1,201 |
11,001 |
165,659 |
0.00%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):